760 completed, 576 recruiting, 459 active not recruiting, 368 terminated. 1608 Phase 2, 953 Phase 1, 348 Phase 3, 39 Early Phase 1, 25 Not applicable.
Follow pembrolizumab: new trials by email Literature Review of pembrolizumab trials Research Report on pembrolizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil - Gastric Cancer, Gastroesophageal-junction Cancer | Phase 3 | Not yet recruiting | Transcenta Therapeutics (Hangzhou) Co., Ltd. | 820 | 2027-06-30 | 2026-09-29 |
| Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab PANDA-VAC, Pembrolizumab - Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer | Phase 1 | Suspended | UNC Lineberger Comprehensive Cancer Center | 6 | 2027-05-20 | 2026-04-23 |
| A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy Larotrectinib, Pembrolizumab - Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 22 | 2027-03-01 | 2026-09-28 |
| Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma Biospecimen Collection, Bone Scan, Computed Tomography - Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 | Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 400 | 2027-02-10 | 2026-07-08 |
| A Clinical Trial Comparing an Antibody (INCA33890) Versus Pembrolizumab for Squamous Cell Carcinoma of the Head and Neck. INCA33890, Pembrolizumab - Head and Neck Cancer Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Groupe Oncologie Radiotherapie Tete et Cou | 78 | 2027-02-01 | 2026-10-22 |
| Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 336 | 2027-01-11 | 2026-08-14 |
| A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs) Carboplatin, Paclitaxcel, Pembrolizumab - Triple Negative Breast Cancer (TNBC), Elevated Tumor-Infiltrating Lymphocytes | Phase 2 | Recruiting | Medical University of South Carolina | 55 | 2027-01-01 | 2026-10-15 |
| Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer Dabrafenib, Trametinib, Pembrolizumab - Anaplastic Thyroid Carcinoma, Thyroid Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 12 | 2026-12-31 | 2026-10-21 |
| Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiota Transplant in Advanced Non-Small Cell Lung Cancer LND101, Carboplatin, Pemetrexed - Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Canadian Cancer Trials Group | 160 | 2026-12-31 | 2026-10-27 |
| Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors ISM5939, Cisplatin, Docetaxel - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Not yet recruiting | InSilico Medicine Hong Kong Limited | 159 | 2026-12-30 | 2026-07-23 |
| Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Carboplatin, Paclitaxel, Nab-paclitaxel - Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Exelixis | 60 | 2026-12-15 | 2026-09-29 |
| Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 374 | 2026-12-04 | 2026-07-08 |
| Labyrinthin Vaccination in Veterans With Lung Adenocarcinoma LabVax 3(22)-23 and GM-CSF (adjuvant) in combination with pembrolizumab - Type and Grade of Toxicities, Demographic and Background Characteristics, Advanced, Metastatic, Recurrent Adenocarcinoma and Malignant Solid Neoplasm | Phase 2 | Not yet recruiting | VA Office of Research and Development | 30 | 2026-12-01 | 2026-10-06 |
| Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma enfortumab vedotin and pembrolizumab (EV/P) - Urothelial Carcinoma (UC) | Phase 2 | Not yet recruiting | University of Florida | 39 | 2026-12-01 | 2026-09-14 |
| N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer Nogapendekin Alfa Inbakicept (NAI), enfortumab vedotin (EV), Pembrolizumab - Metastatic Urothelial Carcinoma, Urothelial Carcinoma | Phase 1 | Not yet recruiting | ImmunityBio, Inc. | 18 | 2026-12-01 | 2026-09-24 |
| Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer EG-007, Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection, Lenvatinib Capsules - Advanced Endometrial Cancer | Phase 3 | Not yet recruiting | Evergreen Therapeutics, Inc. | 450 | 2026-12-01 | 2025-12-08 |
| Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) Pembroluzimab, Observation - HPV-positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Withdrawn | Dana-Farber Cancer Institute | 2026-12-01 | 2026-10-08 | |
| Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall Biospecimen Collection, Computed Tomography, Doxorubicin - Resectable Liposarcoma, Resectable Soft Tissue Sarcoma | Phase 3 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 228 | 2026-12-01 | 2026-09-16 |
| Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma Belzutifan, Pembrolizumab - Locally Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Peter MacCallum Cancer Centre, Australia | 30 | 2026-12-01 | 2026-10-26 |
| PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50% Pembrolizumab, Carboplatin (AUC 5), Cisplatin (75 mg/m²) - Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | German Cancer Research Center | 406 | 2026-11-30 | 2026-10-16 |
Showing 20 of 2579. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (485) · Melanoma (305) · Squamous Cell Carcinoma of Head and Neck (248) · Parkinson Disease 4, Autosomal Dominant Lewy Body (196) · Neoplasms (190) · Triple Negative Breast Neoplasms (172) · Neoplasm Metastasis (167) · Breast Neoplasms (164) · Colorectal Neoplasms (152) · Lung Neoplasms (152) · Carcinoma, Renal Cell (138) · Head and Neck Neoplasms (128) · Stomach Neoplasms (112) · Ovarian Neoplasms (106) · Carcinoma, Transitional Cell (98)
Merck Sharp & Dohme LLC (266) · M.D. Anderson Cancer Center (75) · National Cancer Institute (NCI) (73) · Memorial Sloan Kettering Cancer Center (37) · Dana-Farber Cancer Institute (31) · Mayo Clinic (29) · Eli Lilly and Company (21) · Emory University (20) · University of Chicago (20) · Astellas Pharma Global Development, Inc. (19) · City of Hope Medical Center (19) · GlaxoSmithKline (19) · Washington University School of Medicine (19) · H. Lee Moffitt Cancer Center and Research Institute (18) · Roswell Park Cancer Institute (18)
United States (1731) · Spain (459) · France (377) · South Korea (372) · Italy (347) · China (338) · United Kingdom (337) · Australia (336) · Canada (332) · Germany (312) · Japan (274) · Poland (234) · Taiwan (234) · Belgium (201) · Israel (181)
Mark Jones, MD (6)
PMID 31395089, PMID 35101941, PMID 33300372, PMID 37699333, PMID 32305010, PMID 37465924, PMID 15800326, PMID 38642841, PMID 11698646, PMID 15771580, PMID 18565862, PMID 20516428, PMID 25891174, PMID 27718847, PMID 30202085, PMID 30736858, PMID 32450725, PMID 33360855, PMID 33416261, PMID 33792646, PMID 34754076, PMID 35421228, PMID 35623069, PMID 36648215, PMID 36923556, PMID 37037952, PMID 37598000, PMID 39230120, PMID 39462179, PMID 40117530, PMID 16227604, PMID 17360651, PMID 19188168, PMID 20636820, PMID 23724846, PMID 25891173, PMID 25977344, PMID 25979390, PMID 26028407, PMID 26712084, PMID 27093365, PMID 27138582, PMID 27247226, PMID 27646946, PMID 27745820, PMID 27863197, PMID 28212060, PMID 28271869, PMID 28291584, PMID 29395863
2023 (160), 2018 (64), 2019 (44), 2016 (42), 2017 (39), 2025 (36), 2015 (33), 2014 (20), P30CA138292 (19), U10CA180820 (14), P30CA060553 (13), U10CA180888 (12), P30CA015704 (11), U10CA180868 (10), P30CA033572 (9)